Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy

This is a Phase II, multicenter, randomized open-label and comparative study that has been designed to evaluate whether local consolidative radiotherapy in addition to standard of care improves overall survival as compared with standard of care in patients with regional and/or distant metastatic urothelial bladder cancer who have no disease progression and with no more than three residual distant metastatic lesions following the initial phase of first-line systemic therapy. Each patient will be followed during 4 years from the date of randomization.

NCT Number	NCT04428554
Lead Sponsor	Institut Claudius Regaud
Conditions	Urothelial Bladder Cancer
Enrollment	130 participants
Start Date	2020-06-30
Primary Completion	2031-07 (estimated)
Study Completion	2031-07 (estimated)
Updated on ClinicalTrials.gov	2025-11-18